IASO-782 in Autoimmune Hematological Diseases
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai IASO Biotechnology Co., Ltd
About this trial
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).
Eligibility criteria
Qualifiers
Age 18-65 years
Clinically confirmed diagnosis of autoimmune thrombocytopenia (ITP) or warm autoimmune haemolytic anaemia (wAIHA)
Failure or relapse after at least 1 treatment for the study disease
Stable dose of immunosuppressants for 4 weeks before screening
Disqualifiers
History of other primary malignant neoplasm within 5 years of screening
Secondary to other disease-induced hematopoietic destruction
Cardiac disorder within the last 3 months
Patients with high blood pressure that cannot be controlled by drug
Trial design
Treatments tested in this trial
- IASO-782 injection
- placebo
Treatment groups
16 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov